| Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
| Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare |
2020-09-17 |
| Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC |
2020-09-17 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments |
2020-09-17 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant |
2020-09-17 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech |
2020-09-17 |
| Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications |
2020-09-16 |
| Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact |
2020-09-16 |
| Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 |
2020-09-14 |
| Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital |
2020-09-14 |
| Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital |
2020-09-14 |
| Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners |
2020-09-14 |
| Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax |
2020-09-14 |
| Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona |
2020-09-14 |
| Neogene Therapeutics–Syncona: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Syncona |
2020-09-14 |
| Neogene Therapeutics–Texas Pacific Group: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG |
2020-09-14 |
| Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River |
2020-09-14 |
| Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures |
2020-09-14 |
| Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp |
2020-09-11 |
| MiNA Therapeutics–SEVERAL: investment, 202009 financing round Series A £23m ($30m) led by new investor aMoon + incl existing investors |
2020-09-10 |
| Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
| Algenex–SEVERAL: investment, 202009 private financing round €7.4m led by MasterLux + incl new investor Columbuus Life Science Fund II |
2020-09-08 |
| United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID |
2020-09-08 |
| Amarna Therapeutics–LifeSpring: public relations, 202009 service existent by LifeSpring Communications |
2020-09-03 |
| Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC |
2020-09-03 |
| Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform |
2020-09-02 |
| Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery |
2020-09-02 |
| AstraZeneca–Oxford BioMedica: contract manufacturing, 202009– supply production capacity for adenoviral vector-based Covid-19 vaccine AZD1222 |
2020-09-01 |
| Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform |
2020-09-01 |
| BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m |
2020-09-01 |
| Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 |
2020-09-01 |
| Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b |
2020-08-31 |
| Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures |
2020-08-31 |
| Aignostics–Berlin (govt): investment, 202008 seed financing round totalling €5m incl co-investor VC Fonds Technologie der IBB |
2020-08-28 |
| Aignostics–Boehringer: investment, 202008 seed financing round totalling €5m incl lead investor BIVF |
2020-08-28 |
| Aignostics–Hessen (govt): investment, 202008 seed financing round totalling €5m incl co-investor Future Capital |
2020-08-28 |
| Aignostics–High-Tech Gründerfonds: investment, 202008 seed financing round totalling €5m incl co-investor HTGF |
2020-08-28 |
| Aignostics–SEVERAL: investment, 202008 seed financing round €5m led by BIVF + incl HTGF + IBB VC Fonds Technologie + Future Capital |
2020-08-28 |
| Axol Bioscience–Zyme Communications: public relations, 202008 service existent by Zyme |
2020-08-27 |
| Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction |
2020-08-27 |
| Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer |
2020-08-27 |
| Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures |
2020-08-27 |
| Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors |
2020-08-26 |
| NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders |
2020-08-25 |
| NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall |
2020-08-25 |
| NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders |
2020-08-25 |
| Takeda–Engitix: antifibrotics, 202008– collab + license agreem up to $500m+ developm for advanced liver diseases incl NASH |
2020-08-25 |
| Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system |
2020-08-24 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates |
2020-08-18 |
| Bayer–Hua Medicine: dorzagliatin, 202008– commercialisation agreement + strategic partnership in China |
2020-08-17 |
| Mobilion–SEVERAL: investment, 202008 financing round Series B $35m led by aMoon + incl Agilent + IP Group + Hostplus + Cultivation Capital |
2020-08-17 |
| Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share |
2020-08-17 |
| Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED |
2020-08-13 |
| F2G Ltd–Advent Venture Partners: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences |
2020-08-12 |
| F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments |
2020-08-12 |
| F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital |
2020-08-12 |
| F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures |
2020-08-12 |
| F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos |
2020-08-12 |
| Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF |
2020-08-11 |
| Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV |
2020-08-11 |
| Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF |
2020-08-11 |
| Bayer–Atomwise: AI-based drug discovery, 202008 collab existent |
2020-08-11 |
| Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Kandy Therapeutics–Bayer: investment, 202008– acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones |
2020-08-11 |
| Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer |
2020-08-11 |
| Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital |
2020-08-10 |
| Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share |
2020-08-10 |
| Oasmia–Consilium: public relations, 202008 service existent by CSC |
2020-08-10 |
| T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners |
2020-08-06 |
| T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF |
2020-08-06 |
| T-Knife–RA Capital Management: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor RA Capital |
2020-08-06 |
| T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital |
2020-08-06 |
| T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures |
2020-08-06 |
| GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund |
2020-08-05 |
| GentiBio–OrbiMed: investment, 202008 seed financing round totalling $20m inbcl co-lead investor OrbiMed |
2020-08-05 |
| GentiBio–RA Capital Management: investment, 202008 seed financing round totalling $20m inbcl co-lead investor RA Capital Management LP |
2020-08-05 |
| GentiBio–SEVERAL: investment, 202008 seed financing round $20m led by OrbiMed + Novartis Venture + RA Capital Management |
2020-08-05 |
| Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures |
2020-08-05 |
| NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum |
2020-08-03 |
| Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED |
2020-08-02 |
| Genespire–Consilium: public relations, 202007 service existent by CSC |
2020-07-30 |
| DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital |
2020-07-29 |
| Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications |
2020-07-29 |
| Abzena–Biospring Partners: investment, 202007 investment $10m by Lifespring Partners |
2020-07-28 |
| Enthera–AbbVie: investment, 202007 financing round Series A totalling €28m incl new + co-lead investor AbbVie Ventures |
2020-07-28 |
| Enthera–Banca Profilo: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Arepo Fiduciaria |
2020-07-28 |
| Enthera–Banor SIM: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Banor SIM |
2020-07-28 |
| Enthera–Indaco Venture Partners: investment, 202007 financing round Series A totalling €28m incl new + co-investor Indaco Venture Partners SGR |
2020-07-28 |
| Enthera–Instinctif Partners: public relations, 202007 service existent by Instinctif |
2020-07-28 |
| Enthera–Juvenile Diabetes Research Foundation: investment, 202007 financing round Series A totalling €28m incl existing + co-investor JDRF T1D Fund |
2020-07-28 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date![Picture [iito] No Tracking 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-tracking.jpg){kind=tracking}
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
